Why This NYSE Biotech Matters in 2026

Momentum is building fast

March 27, 2026

*together with NanoViricides

Why NanoViricides (NNVC) Could Be One of the Most Explosive Antiviral Stories of the Year!

NanoViricides (NYSE: NNVC) is not trying to outcompete traditional antivirals—it’s trying to replace the entire model. Its lead drug candidate, NV-387, uses biomimicry to trap viruses by imitating the same host-cell attachment points that over 90% of viruses rely on to infect humans. 

This approach has shown effectiveness in animal models against MPox, Smallpox, Measles, RSV, Influenza, and COVID, positioning NV-387 as a potential first-response antiviral for future outbreaks. Unlike vaccines or antibodies that can be rendered obsolete by viral mutation, NV-387 is designed to remain effective precisely because viruses must keep binding to these receptors to survive.

Momentum is building fast. NNVC has secured approval to launch a Phase II MPox trial in Africa, is pursuing orphan drug designation with guidance from a former FDA insider, and has strengthened its balance sheet with recent institutional funding. 

At the same time, global health conditions are deteriorating—measles cases are surging, MPox is spreading into new populations, and pandemic readiness remains dangerously thin. If NV-387 continues to advance, NNVC could move from a speculative biotech to a critical player in global antiviral defense. 

With orphan drug incentives potentially granting market exclusivity, tax credits, and expedited FDA review, NV-387 could reach patients faster while creating a rare combination of medical and financial upside for investors.

DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC (“SV”). Full disclaimer: https://bullseyealerts.com/disclaimer/.

NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security.

*PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received six thousand dollars cash (via Interactive Offers) for this one day program on 3/27/26 for marketing efforts to increase public awareness of this company. SV has also previously been compensated for similar marketing efforts. As SV has received compensation from these companies, these parties have financial interests in the securities referenced. Further, SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice.

RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions.